...
首页> 外文期刊>Journal of Medical Virology >Successful treatment of aciclovir and foscarnet resistant Herpes simplex virus lesions with topical imiquimod in patients infected with human immunodeficiency virus type 1.
【24h】

Successful treatment of aciclovir and foscarnet resistant Herpes simplex virus lesions with topical imiquimod in patients infected with human immunodeficiency virus type 1.

机译:1型人类免疫缺陷病毒感染的患者使用局部咪喹莫特成功治疗了耐阿昔洛韦和膦甲酸的单纯疱疹病毒病灶。

获取原文
获取原文并翻译 | 示例
           

摘要

Aciclovir (ACV)-resistant Herpes simplex virus type-2 (HSV-2) infections are observed commonly in patients also infected with HIV-1. The use of foscarnet (FOS) in these patients may also lead to resistance. This situation can become a difficult therapeutic challenge. Four cases of patients infected with HIV and with mucocutaneous HSV-2 resistant to ACV and FOS are reported. These patients were treated successfully with topical 5% imiquimod. Imiquimod treatment also appeared to delay the time to recurrence of HSV lesions.
机译:耐阿昔洛韦(ACV)的2型单纯疱疹病毒(HSV-2)感染通常也感染HIV-1。在这些患者中使用膦甲酸(FOS)也可能导致耐药。这种情况可能成为困难的治疗挑战。据报道,有四例患者感染了艾滋病毒,并对ACV和FOS产生了粘膜皮肤HSV-2感染。这些患者均已成功接受5%咪喹莫特局部治疗。咪喹莫特治疗也似乎延迟了HSV病变复发的时间。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号